Medizone International's AsepticSure sterilization system eradicates all Super Bugs

Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that every full scale test run completed thus far in its hospital room mock up facility has resulted in the total elimination of all bacteria present in the room. In this current phase of development, Medizone's scientific team will attempt to confirm, in a more realistic hospital setting, recent laboratory findings indicating extremely high antibacterial efficacy for its novel technology (6-7.2 log reductions) against the primary causative agents of hospital acquired infections (HAIs), sometimes referred to as "Super Bugs".   Dr. Michael Shannon, Medizone's Director of Medical Affairs commented, "From the very onset, our new scaled up sterilization system performed magnificently.  We have now completed multiple runs with very high concentrations of MRSA, VRE and E. coli samples that were distributed throughout the test room.

In every instance, the AsepticSure™ system produced greater than 6 log (99.9999%) reductions, which by definition, is sterilization. It is noteworthy in this regard that there was absolutely no growth on any of the artificially contaminated surfaces exposed to the AsepticSure™ process." Shannon continued, "Our intention now is to systematically collect empirically verifiable scientific data on all the remaining causative agents of HAIs.  Given these recent results in a full room test setting which precisely mirrors our laboratory set up, we fully expect the same results with all remaining bacteria as well as Bacillus subtilis, the recognized surrogate for Anthrax. Thus, while more testing and data acquisition must be completed before moving into hospital beta testing, it now seems certain that AsepticSure™ will deliver as promised."

Medizone's CEO Edwin Marshall added, "One of our concerns from the beginning has been the protection of the very expensive electronics found throughout hospitals. We have been testing electronic devices exposed to our process from the very beginning of our laboratory trials.  While our electronic testing program will now be intensified to assure we are not making false assumptions, it is encouraging to note that one highly sensitive electronic instrument has now undergone over 50 exposures to our protocol, many at much higher O3 concentrations than we are now using, and it still performs as if it was brand new."